We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
Read MoreHide Full Article
In line with its expected time of conclusion, Thermo Fisher ScientificInc. (TMO - Free Report) recently announced the completion of its previously-declared sale of its Anatomical Pathology business. The arm, as was notified in January 2019, has been sold to PHC Holdings Corporation, a global innovator in healthcare solutions for approximately $1.14 billion in cash.
The Anatomical Pathology business of Thermo Fisher would fall under its Specialty Diagnostics segment that serves customers in healthcare and clinical laboratories. Last year, this segment contributed more than 15% to the company’s top line. Over the past year, this segment had steadily generated positive revenue growth. The Anatomical Pathology subsegment alone generates approximately $350 million in annual revenues.
Undoubtedly, this divestiture is going to put pressure on the company's earnings performance. Thermo Fisher currently expects the net dilution of this divestment to 2019 adjusted earnings per share to be approximately 10 cents.
Following the news of this divestment’s closure, the stock slid 0.3% to close at $293.68 last Friday.
The Rest of Specialty Diagnostics Holds Potential
On a positive note, Thermo Fisher’s broader Specialty Diagnostics business is booming with huge potential at the moment. The company has received an FDA clearance for a new ImmunoCAP test for peanut allergies. This blood test is designed to help doctors better identify patients who are highly sensitive to a certain protein in peanuts that can cause severe allergic reactions. According to Thermo Fisher, this can be a game changer for patients in terms of appropriately managing their allergy and preventing a life-threatening event.
We are currently looking forward to Thermo Fisher’s five-year plan that outlines investments in innovation, healthcare and environment. Per the company, increasing growth scale in the emerging markets is a key competitive edge that fetches significant client wins. The company is also looking at expanding its manufacturing footprint to serve the local markets and capitalize on demand for Specialty Diagnostics.
Over the past three months, shares of Thermo Fisher have outperformed its industry. The stock has gained 6.9% compared with the industry’s 1.5% rise.
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
CONMED’s long-term earnings growth rate is estimated at 13.3%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
Thermo Fisher's Unit Sale May Not Ail Specialty Diagnostics
In line with its expected time of conclusion, Thermo Fisher Scientific Inc. (TMO - Free Report) recently announced the completion of its previously-declared sale of its Anatomical Pathology business. The arm, as was notified in January 2019, has been sold to PHC Holdings Corporation, a global innovator in healthcare solutions for approximately $1.14 billion in cash.
The Anatomical Pathology business of Thermo Fisher would fall under its Specialty Diagnostics segment that serves customers in healthcare and clinical laboratories. Last year, this segment contributed more than 15% to the company’s top line. Over the past year, this segment had steadily generated positive revenue growth. The Anatomical Pathology subsegment alone generates approximately $350 million in annual revenues.
Undoubtedly, this divestiture is going to put pressure on the company's earnings performance. Thermo Fisher currently expects the net dilution of this divestment to 2019 adjusted earnings per share to be approximately 10 cents.
Following the news of this divestment’s closure, the stock slid 0.3% to close at $293.68 last Friday.
The Rest of Specialty Diagnostics Holds Potential
On a positive note, Thermo Fisher’s broader Specialty Diagnostics business is booming with huge potential at the moment. The company has received an FDA clearance for a new ImmunoCAP test for peanut allergies. This blood test is designed to help doctors better identify patients who are highly sensitive to a certain protein in peanuts that can cause severe allergic reactions. According to Thermo Fisher, this can be a game changer for patients in terms of appropriately managing their allergy and preventing a life-threatening event.
We are currently looking forward to Thermo Fisher’s five-year plan that outlines investments in innovation, healthcare and environment. Per the company, increasing growth scale in the emerging markets is a key competitive edge that fetches significant client wins. The company is also looking at expanding its manufacturing footprint to serve the local markets and capitalize on demand for Specialty Diagnostics.
Over the past three months, shares of Thermo Fisher have outperformed its industry. The stock has gained 6.9% compared with the industry’s 1.5% rise.
Zacks Rank & Other Key Picks
Thermo Fisher holds a Zacks Rank #2 (Buy). A few other top-ranked stocks in the broader medical space are DENTSPLY SIRONA (XRAY - Free Report) , Penumbra (PEN - Free Report) and CONMED Corporation (CNMD - Free Report) , each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
CONMED’s long-term earnings growth rate is estimated at 13.3%.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>